WASHINGTON--(BUSINESS WIRE)--Cappella Inc., developer of advanced stenting systems for the treatment of coronary bifurcation disease announced today that it will participate in a live animal case featuring the Sideguard™ side branch stent, and will present results of its successful pre-clinical studies at the Cardiovascular Research Foundation’s (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
